Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Cetuximab + Encorafenib |
| Indication/Tumor Type | colon cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | colon cancer | sensitive | Cetuximab + Encorafenib | Case Reports/Case Series | Actionable | In a clinical case study, neoadjuvant treatment with the combination of Braftovi (encorafenib) and Erbitux (cetuximab) resulted in tumor reduction in 2 patients with locally advanced, right-sided colon cancer harboring BRAF V600E (PMID: 40373261). | 40373261 |
| BRAF V600E | colon cancer | sensitive | Cetuximab + Encorafenib | Guideline | Actionable | Braftovi (encorafenib) in combination with Erbitux (cetuximab) is included in guidelines as primary or subsequent therapy for patients with colon cancer harboring BRAF V600E (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... | |
| (40373261) | Neoadjuvant Encorafenib Plus Cetuximab in BRAF-V600E-Mutated Locally Advanced Colon Cancer. | Full reference... |